Cellceutix Corp. (CTIX.OB) Presents Poster on Kevetrin at American Association for Cancer Research
Cellceutix Corp. presented a poster yesterday at the American Association for Cancer Research (AACR) 101st Annual Meeting in Washington, D.C. on their lead drug, Kevetrin™. The poster was titled "Novel Small Molecule has Potent Anti-tumor Activity in Drug Resistant Human Carcinoma Xenograft Models.” Cellceutix is developing Kevetrin for treatment of specific cancer cell lines that are proven to be resistant to standard anti-cancer treatments. The poster presented new data that had not yet been released to the public regarding further research on Kevetrin as it approaches human trials. The data from the research showed two significant results in the mouse…